Takeda Pharmaceutical Company Limited
TAKHealthcareNASDAQDrug Manufacturers - Specialty & Generic · Last scanned Oct 26, 2026
Scan Results
Daily timeframeTakeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products. The $64.66B market capitalization puts TAK squarely in large-cap range for its industry. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma-derived therapies, oncology, vaccines, and neuroscience.
Market Cap
$64.66B
Beta
0.10
P/E (TTM)
—
P/E (Fwd)
38.19
EPS (TTM)
$-0.34
EPS (Fwd)
$0.53
ROE
-2.3%
ROA
2.7%
Cash
$460.98B
Total Debt
$5.54T
Free CF
$541.44B
52W Change
42.8%
Annual Financials
Cash vs Debt
Where TAK stands vs its 150-day and 200-day moving averages
As of the October 19, 2026 close, TAK finished 13.50% above its 150-day moving average ($17.33) and 13.44% above its 200-day moving average ($17.34). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is TAK overbought or oversold?
At the October 19, 2026 close, TAK's RSI(14) was 61.4, in neutral territory (between 30 and 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
The company holds $460.98B in cash, though total debt stands at $5.54T. This level of leverage is common in the industry but worth monitoring as interest rate conditions evolve. Annual free cash flow of $541.44B supports ongoing capital allocation decisions and provides a cushion against unexpected expenses or downturns. Return on equity stands at -2.3%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. ROA of 2.7% is on the lower side, which is common in asset-heavy industries. Revenue has been uneven over recent years, ranging from $4.03T to $4.51T.
The relatively low beta of 0.10 suggests TAK is a less volatile holding compared to the broader index. Takeda Pharmaceutical Company Limited carries a heavier debt load relative to its cash position, which introduces financial risk that investors should weigh. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence Takeda Pharmaceutical Company Limited's trajectory.